论文部分内容阅读
目的探讨瑞舒伐他汀对急性脑梗死患者血清血管抑制因子(VS-2)、可溶性细胞黏附因子-1(sI-CAM-1)和基质金属蛋白酶(MMP2)水平的影响。方法选取2014年7月至2016年1月急性脑梗死患者80例,依入院顺序分为两组,每组40例。两组患者均予以常规治疗,观察组患者在常规治疗基础上给予瑞舒伐他汀,两组治疗均持续2周。对比治疗前后两组VS-2、sI-CAM-1和MMP2水平、血浆血栓调节蛋白(TM)、血管性假血友病因子(vWF)水平及药物不良反应发生率。结果两组治疗后VS-2、sI-CAM-1和MMP2水平较治疗前均降低,观察组下降水平优于对照组,差异有统计学意义(P<0.05);两组TM、vWF与治疗前比较均降低,观察组下降水平优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论瑞舒伐他汀治疗急性脑梗死效果显著,不增加药物不良反应,显著降低患者血清VS-2、sI-CAM-1、MMP2及血浆TM、vWF水平。
Objective To investigate the effect of rosuvastatin on the levels of serum vascular smooth muscle cell adhesion molecule-1 (sI-CAM-1) and matrix metalloproteinase (MMP2) in patients with acute cerebral infarction. Methods Eighty patients with acute cerebral infarction from July 2014 to January 2016 were divided into two groups according to the order of hospital admission, 40 cases in each group. Patients in both groups were given routine treatment. Patients in observation group were given rosuvastatin on the basis of routine treatment, and both groups were treated for two weeks. The levels of VS-2, sI-CAM-1 and MMP2, plasma thrombomodulin (TM), von Willebrand factor (vWF) levels and adverse drug reactions in both groups were compared before and after treatment. Results After treatment, the levels of VS-2, sI-CAM-1 and MMP2 in both groups were lower than those before treatment, and the decrease in the observation group was better than that in the control group (P <0.05) (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusions Rosuvastatin is effective in treating acute cerebral infarction. It does not increase adverse drug reactions and significantly decreases the serum levels of VS-2, sI-CAM-1, MMP2 and plasma TM and vWF.